Irinotecan, Cisplatin, and Etoposide for Sensitive Relapsed Small-Cell Lung Cancer
Author Information
Author(s): K Goto, I Sekine, Y Nishiwaki, R Kakinuma, K Kubota, T Matsumoto, H Ohmatsu, S Niho, T Kodama, T Shinkai, T Tamura, Y Ohe, H Kunitoh, N Yamamoto, H Nokihara, K Yoshida, T Sugiura, K Matsui, N Saijo
Primary Institution: National Cancer Center Hospital East
Hypothesis
The study aims to evaluate the efficacy and toxicities of a combination chemotherapy regimen (irinotecan, cisplatin, and etoposide) in patients with sensitive relapsed small-cell lung cancer.
Conclusion
The PEI regimen is a highly active and well-tolerated treatment for sensitive relapsed small-cell lung cancer.
Supporting Evidence
- Three complete responses and thirteen partial responses were observed in 18 analyzed patients, resulting in a response rate of 89%.
- The median survival time was 11.8 months with a 1-year survival rate of 49%.
- Severe toxicities were mainly haematological, with 73% of patients experiencing grade 3-4 neutropenia.
Takeaway
This study tested a new combination of drugs to help patients with a type of lung cancer that comes back after treatment, and it worked well for many of them.
Methodology
The study involved two phase II trials evaluating the efficacy and toxicities of the PEI regimen in patients with sensitive and refractory relapsed SCLC.
Potential Biases
Potential selection bias due to the inclusion criteria focusing on patients with good performance status.
Limitations
The study only included patients with sensitive relapsed SCLC, which may limit the generalizability of the results to all relapsed SCLC patients.
Participant Demographics
The median age of participants was 67 years, with 73% male and 27% female.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI, 65.3–98.6%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website